














































































































Adipose	 tissue	 consists	 of	 adipocytes	 which	 are	 cells	 specialized	 in	 storing	 large	
quantities	 of	 energy	 found	 in	 vertebrates	 [1].	 Each	 adipocyte	 is	 surrounded	 by	
connective	 tissue	 of	 basal	 lamina,	 reticular	 and	 collagen	 fibers	 that	 hold	 the	 cells	
together	 as	 connective	 tissue.	 Segments	 of	 adipose	 tissue	 are	 provided	with	 nerves	
and	 blood	 vessels	 which	 ensure	 communication	 with	 other	 cells	 and	 tissues	 of	 the	
human	 body	 [2].	 Depending	 on	 the	 gender,	 age	 and	 health	 status	 the	 content	 of	
adipose	 tissue	 in	 the	body	can	vary	 from	approximately	6%	 in	man	athletes	 to	more	
than	32%	in	obese	 individuals	[3].	Despite	acting	as	an	energy	storage	adipose	tissue	
fulfils	 several	 important	 functions	 in	 the	 organism.	 Adipocytes	 contribute	 to	 the	










levels	 whereas	 WAT	 located	 intra-abdominal	 (visceral)	 appears	 to	 negatively	 affect	
metabolism	 [4].	 Furthermore,	 subcutaneous	 adipose	 tissue	 serves	 as	 isolator	 from	
temperature	changes	 in	environment	and	protects	from	loss	of	body	heat.	Depots	of	
adipose	 tissue	also	cushion	 important	parts	of	 the	body	exposed	 to	high	mechanical	
pressure	such	as	 the	heel.	Additionally,	 fat	depots	ensure	 the	position	of	organs	e.g.	
















Certain	 histological	 differences	 distinguish	 white	 from	 brown	 adipocytes.	 In	
adipocytes,	 fat	 accumulates	 in	 lipid	 droplets	 surrounded	 by	 a	 phospholipid	 layer	
containing	 perlipin-1	 which	 forms	 a	 vacuole	 separated	 from	 other	 cell	 organelles.	
While	 white	 adipocytes	 rather	 appear	 with	 one	 vacuole,	 brown	 adipocytes	 contain	
many	 smaller	 lipid	 droplets	 [2,	 9].	 Furthermore,	 brown	 adipocytes	 display	 a	 high	
density	of	mitochondria	that	 lay	the	basis	 for	their	 function:	The	 inner	mitochondrial	
membrane	contains	uncoupling	protein-1	 (UCP-1),	 a	protein	expressed	 specifically	 in	
brown	 adipocytes	 [1,	 2,	 9].	 UCP-1,	 also	 called	 thermogenin,	 is	 responsible	 for	
thermogenesis	 by	 BAT.	 While	 the	 respiratory	 chain	 in	 mitochondrial	 membrane	
generates	 a	 proton	 gradient	 necessary	 to	 produce	 energy	 in	 form	 of	 ATP,	 UCP-1	
establishes	 a	 back	 current	 for	 protons.	 Therefore,	 it	 uncouples	 the	 mechanism	 of	
respiratory	chain	and	produces	energy	in	form	of	heat.	Stimulation	of	the	sympathetic	
nervous	 system	 and	 catecholamine	 secretion	 in	 BAT	 induce	 increase	 of	 intracellular	
cyclic	adenosine	monophosphate	(cAMP)-levels	and	lipolysis	(detail	in	1.1.2).	Free	fatty	
acids	that	are	generated	by	 lipolysis	metabolize	 in	mitochondria	and	 its	products	are	
important	 for	 respiratory	 chain.	 Additionally,	 high	 cAMP	 concentration	 leads	 to	
transcription	 of	 UCP-1	 and	 therefore	 enhance	 production	 of	 heat	 [10].	 Hence,	 BAT	
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lipid	droplets,	 high	density	of	mitochondria,	 and	expression	of	UCP-1	with	 the	 same	
function	 in	 heat	 production	 as	 in	 brown	 adipocytes.	 Although	 the	 origin	 of	 beige	
adipocytes	is	controversially	discussed,	they	appear	to	develop	from	white	adipocytes	
by	 induction	with	 PPARγ-agonist,	 adrenergic	 stimulation,	 exercise,	 or	 cold	 exposure.	
This	 process	 is	 called	 “browning”	 or	 “beiging”	 of	 WAT.	 Similar	 to	 brown,	 beige	
adipocytes	possess	a	 large	number	of	mitochondria	and	express	UCP-1,	which	allows	
them	 to	 dissipate	 energy	 in	 the	 form	 of	 heat	 [1,	 5,	 12].	 However,	 recently	 a	 novel	
mechanism	 of	 heat	 dissipation	 utilized	 primarily	 by	 beige	 adipocytes	 has	 been	
proposed.	 Proteomic	 study	 revealed	 that	 beige	 adipocytes	 possess	 creatine	 enzyme	
driven	substrate	cycle	that	enhances	thermogenesis.	Creatine	drives	energy	dissipation	
by	mitochondria	of	beige	adipocytes	by	accepting	phosphate	group	from	ATP	and	 its	
subsequent	 release	 in	 the	 process	 mediated	 by	 phosphatase	 PHOSPHO1.	 The	 same	




In	vertebrates,	adipocytes	have	an	evolutionary	 important	 function	and	 lay	 the	basis	
for	 survival	 of	 living	 organism:	 They	 store	 energy	 at	 times	 of	 nutritional	 abundance	




Lipid	 droplets	 in	 adipocytes	 consist	 of	 triacylglycerides	 (TGs)	 stored	 without	 water.	
Therefore	TGs	have	a	higher	energy	density	 than	carbohydrates,	which	are	stored	as	
glycogen	with	water	 in	 liver	and	muscles	 [9].	Lipolysis,	 the	process	of	breaking	down	
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TGs,	 is	 induced	 during	 fasting	 or	 can	 be	 stress	 mediated,	 promoted	 by	 several	
hormones	among	which	catecholamines	are	of	greatest	importance.	Variables	such	as	
inflammation,	 oncological,	 genetic,	 metabolic	 and	 endocrine	 diseases,	 can	 alternate	
the	rate	of	lipolysis	[14].	Three	enzymes,	adipose	triglyceride	lipase	(ATGL),	hormone-





needy	 organs	 with	 energy.	 They	 either	 undergo	 b-oxidation	 in	 mitochondria,	 which	




in	 the	process	of	 lipogenesis.	 TGs	 are	 synthesized	 from	 fatty	 acids	 and	glycerol	with	
monoacylglycerolphosphate	 and	 1,2-diacylglycerol	 as	 intermediate	 steps	 [10].	 There	
are	two	ways	to	expand	capacity	for	fat	deposition:	First,	by	hypertrophy	of	cells	and	
second,	due	to	a	limit	in	adipocyte	size	by	hyperplasia	in	the	process	of	adipogenesis.	
Although	 this	mechanism	 is	 important	 for	 organisms	 survival,	 it	 is	 also	 the	 basis	 for	







Additionally,	 adipocytes	 act	 as	 an	 endocrine	 organ	 and	 secret	 adipokines	 which	
regulate	food	consumption,	energy	expenditure,	and	also	peripheral	insulin	sensitivity.	





Adiponectin	 is	 another	 adipokine	 produced	 by	 adipocytes.	 Adiponectin	 has	 positive	
effects	 on	 metabolic	 health	 by	 improving	 β-cell	 function	 together	 with	 insulin	
sensitivity,	 serum	 lipid	 levels	 and	 inducing	metabolization	 of	 fatty	 acids	 in	 the	 liver	
[18].		




induced	by	drop	of	blood	glucose	 level	as	well	as	 cold	exposure	 lead	 to	 secretion	of	
catecholamines	epinephrine	and	norepinephrine.	These	bind	to	β-adrenergic	receptors	
located	 at	 adipocyte	 cell	 membrane	 and	 activate	 a	 signaling	 cascade	 to	 increase	
lipolysis	[20].	On	the	other	hand,	parasympathetic	nerves	are	stimulated	after	feeding	





excessive	 TG	 accumulation	 in	 these	 cells	 result	 in	 obesity	 [22].	 Globally	 speaking,	
obesity	 is	 caused	 by	 an	 imbalanced	 energy	 equation	 resulting	 from	 an	 increased	
energy	 intake	 of	 high	 caloric	 foods	 as	well	 as	 insufficient	 caloric	 expenditure	 of	 the	
body	 via	 physical	 activity,	 basal	 metabolism,	 and	 adaptive	 thermogenesis.	 Genetic,	
environmental,	 and	 psychological	 factors	 influence	 this	 equation	 [22,	 23].	 In	 clinical	
means,	 obesity	 is	 classified	 using	 the	 Body	 Mass	 Index	 (BMI,	 [kg/m2]),	 which	 is	




5	years	old	were	 found	to	be	obese	or	overweight	 (BMI	equal	or	greater	 than	25)	 in	
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2016,	 which	 is	 associated	with	 their	 future	 obesity,	 disability,	 and	 premature	 death	




the	 main	 component	 of	 the	 metabolic	 syndrome	 [24].	 The	 International	 Diabetes	





factors,	 raised	 fasting	plasma	glucose	 levels	 or	 previously	diagnosed	 type	2	diabetes	
mellitus	 (T2DM)	 [24].	 Emphasis	 is	 put	 on	 the	 factor	 abdominal	 obesity,	 which	 is	
associated	especially	with	development	of	T2DM	but	also	with	 the	other	 risk	 factors	
listed	 in	 the	definition	of	metabolic	 syndrome.	Low	HDL	cholesterol	and	elevated	TG	
blood	levels	can	be	summoned	as	atherogenic	dyslipidaemia,	which	is	found	in	humans	
with	 metabolic	 syndrome	 and	 T2DM.	 The	 link	 between	 each	 listed	 risk	 factor	 is	
complex	but	 they	are	most	 important	 for	development	of	cadiocascular	disease.	 It	 is	
generally	 accepted	 that	 the	 metabolic	 syndrome	 is	 a	 combination	 of	 the	 most	
dangerous	risk	 factors	 to	cause	heart	attack	or	stroke	 [24].	 In	 fact,	 the	World	Health	
Organization	(WHO)	listed	ischaemic	heart	disease	with	8.67	million	deaths	as	the	first	
leading	 cause	 for	 death	 worldwide	 in	 the	 year	 2015,	 followed	 by	 stroke	 with	 6.24	
million	deaths	 as	 the	 second	 leading	 cause,	 and	diabetes	mellitus	 (DM)	on	 the	 sixth	
place	[25].	Most	importantly,	the	number	of	deaths	caused	by	DM	increased	from	less	
than	1	million	 in	 2010	 to	 1.59	million	 in	 2015	 [25].	Hence,	metabolic	 syndrome	and	
diseases	associated	with	it	form	a	big	threat	for	the	well-being	of	our	society.	
	










can	eventually	 outgrow	 its	 blood	 supply	which	 causes	hypoxia	 in	 the	 tissue	 [1].	 This	
leads	to	macrophage	invasion	and	cytokine	secretion,	including	TNF-α	(tumor	necrosis	
factor	α),	resistin,	MCP-1	(macrophage	chemoattractant	protein-1)	and	others,	and	in	
essence	 to	 inflammation	 in	WAT.	 In	 addition,	 fibrosis	 may	 develop,	 which	 supports	
inflammatory	progress	[9].	Pro-inflammatory	cytokines	were	found	to	negatively	affect	
insulin	sensitivity	not	only	in	adipocytes	but	also	in	liver	and	muscle	[1].	However,	an	
other	 study	 proposed	 that	 increase	 of	 fibrosis	 in	 adipose	 tissue	 restricts	 adipocyte	
hypertrophy,	 which	 is	 beneficial	 for	 metabolic	 health	 and	 is	 therefore	 protective	
against	 T2DM	 [28].	 In	 addition	 to	 the	 inflammatory	 process,	 adipocytes	 endocrine	
function	 alters	 in	 obese	 individuals	 and	 contributes	 to	 decreased	 insulin	 sensitivity.	
Secretion	of	adiponectin	for	instance	decreases	with	gain	of	visceral	fat	and	therefore	
its	positive	effects	on	insulin	sensitivity	diminish	in	obese	individuals.	Resistin	levels	on	
the	other	hand	are	 increased	 in	obese	mice	and	 cause	elevated	 insulin	 resistance	 in	
them.	 Although	 leptin	 is	 helpful	 in	 reducing	 body	 weight	 (1.1.2),	 it	 also	 enhances	
cytokine	 production	 and	 therefore	 stimulates	 inflammation.	 Leptin	 blood	 levels	
correlate	with	mass	 of	 fat	 [1,	 9,	 22].	 All	 in	 all,	 these	mechanisms	 show	 that	 chronic	
inflammation	is	associated	with	obesity	and	inflammation	results	in	peripheral	insulin	
resistance	 and	 eventually	 in	 T2DM	 [29].	 Insulin	 resistance	 in	 adipose	 tissue	 leads	 to	
release	of	FFA	into	blood	circulation	[9].	When	reaching	liver,	FFA	induce	elevation	of	
LDL	 (low	 density	 lipoprotein	 cholesterol),	 apolipoprotein	 B	 and	 TG	 whereas	 HDL	 is	
reduced.	 This	 atherogenic	 dyslipidaemia	 significantly	 increases	 not	 only	 the	 risk	 for	





suffered	 from	 T2DM.	 Consequences	 of	 DM	 include	 high	 risk	 of	 death	 from	
cardiovascular	 disease,	 in	 detail	 heart	 attack	 and	 stroke,	 risk	 of	 neuropathy	 and	
reduced	blood	 flow,	which	 can	 result	 in	 lower	 limb	 loss,	 and	 risk	of	 retinopathy	and	
kidney	failure	[27].	
	
Apart	 from	 metabolic	 disease,	 obesity	 is	 associated	 with	 development	 of	 certain	
cancer	 types	 such	 of	 endometrium,	 breast,	 colon,	 renal,	 esophageal,	 and	 pancreatic	
cancer	[1,	23].	
Thus,	 it	 is	 of	 great	 importance	 for	 the	 future	 of	 human	 global	 health	 to	 promote	




PKD1	 belongs	 to	 a	 group	 of	 isoforms	 in	 the	 protein	 kinase	 D	 (PKD)	 family	 of	
serine/threonine	kinases	 [30].	The	PKD	family	 is	classified	 in	 the	calcium/calmodulin-
dependent	 protein	 kinases	 (CAMKs)	 superfamily	 due	 to	 similarities	 of	 the	 kinase	
domain.	There	are	three	different	 isoforms	of	PKDs	 in	mammals	with	different	tissue	
and	 cell	 expression:	 PKD1	 (also	 referred	 to	 as	 PKCμ),	 PKD2,	 and	 PKD3	 (also:	 PKCν)	
sharing	a	similar	modular	structure	but	encoded	in	three	different	genes.	PKDs	exhibit	
an	 N-terminal	 regulatory	 domain	 containing	 two	 cystein-rich	 zink-finger	 motifs	
(cysteine-rich	 domain,	 CRD)	 and	 an	 autoinhibitory	 pleckstrin	 homology	 (PH)-domain.	
More	 specifically,	 the	 CRD	 binds	 to	 diacylglycerol	 (DAG)	 and	 phorbol	 esters	 to	
translocate	the	kinase	to	plasma	membrane	and	nucleus	and	has	an	 inhibitory	effect	
on	the	kinase	catalytic	activity.	Mutation	of	PH-domain	or	deletion	of	zink-fingers	from	


















has	 been	 shown	 that	 on	 the	 one	 hand	 mutation	 at	 Ser-744	 and	 Ser-748	 leads	 to	
inability	of	PKD1	activation,	on	 the	other	hand	 imitation	of	phosphorylation	 through	
mutation	at	 these	sites	creates	a	constitutively	active	kinase	 [32].	Additionally,	PKD1	
has	the	ability	to	auto-phosphorylate	Ser-916	(pSer-916,	in	murine	PKD1)	at	the	far	C-
terminal	end	 for	conformational	changes	 in	PKD1.	For	 this	 step,	phosphorylated	Ser-
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744	 (pSer-744)	 is	 required,	 and	 furthermore,	 pSer-916	 is	 necessary	 for	 auto-
phosphorylation	of	Ser-748.	Therefore,	PKDs	activity	can	be	traced	by	using	antibodies	
against	 pSer-744/748	 or	 against	 pSer-916	 [30].	 Of	 note,	 that	 these	 phosphorylation	
sites	apply	 for	mice	and	differ	 from	human	PKD1	 (Ser-738/Ser-742	 in	activation	 loop	
and	Ser-910	at	far	N-terminal	end)	[33].	
There	is	a	pool	of	PKD1	located	mainly	 in	the	cytosol	of	resting	cells.	Upon	G-protein	
coupled	 receptor	 (GPCR)	 or	 tyrosine-kinase	 receptor	 (TKR)	 stimulation	 of	 cells,	
Phosolipase	 C	 (PLC)	 is	 activated	 leading	 to	 the	 generation	 of	 DAG	 at	 the	 plasma	
membrane	 to	 bind	 and	 activate	 PKC,	 (Figure	1)	 [30].	 Study	 showed	 that	 the	 1,2-DAG	
stereoisomer	 fulfills	 activation	 of	 PKC,	 which	 is	 provided	 by	 PLC-pathway	 at	 plasma	
membrane	[34].		
As	 mentioned	 before,	 PKDs	 use	 the	 CRD	 for	 translocation	 in	 cells.	 Therefore,	 PLC-
produced	 DAG	 also	 binds	 to	 PKDs	 second	 zink-finger	 domain	 in	 CRD	 (C1b).	 It	 then	
translocates	via	the	second	zink-finger	domain	to	the	plasma	membrane.	Attached	to	
the	plasma	membrane,	activated	PKC	phosphorylates	PKD	in	the	activation	loop	at	Ser-




Yet,	PKD	 isoforms	can	be	activated	at	other	 subcellular	 location.	The	 first	 zink-finger	
domain	 (C1a)	 of	 CRD	 determines	 PKDs	 translocation	 into	 the	 trans-Golgi	 network	








PKD1	 is	 located	within	 the	 cell	 cytosol,	 TGN,	 nucleus,	 and	mitochondria	 and	 can	 be	
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activated	 via	 the	 PKC-pathway	 in	 vivo	 through	 neuropeptides,	 purinergic	 receptor	
activation,	 growth	 factors,	 neurotensin	 and	 many	 more,	 next	 to	 DAG	 and	 phorbol	
esters	 [30,	 31,	 36,	 37].	 Specific	 substrates	 and	 changes	 in	 sub-cellular	 localization	
determine	its	function	and	the	resulting	biological	effect	[38].	
	
However,	 PKD	 also	 displays	 PKC-independent	 pathways	 for	 activation.	 A	 Src-Abl-
pathway	mediates	phosphorylation	of	PKD1	at	 the	PH-domain	 through	 the	action	of	
tyrosine	[37].	Moreover,	PKD1	is	a	substrate	of	caspase-3	and	is	regulated	in	apoptosis,	
during	which	 cleavage	 of	 PKD1	 at	 two	 sites	 showed	 increase	 of	 the	 kinases	 activity	
[39].	M3-muscarin	receptors	were	also	shown	to	activate	PKD1	in	pancreatic	β-cells	via	
direct	phosphorylation	in	a	β-arrestin-dependent	manner	[40].		
Recently,	 Chang	 et	 al.	 demonstrated	 that	 stimulation	 with	 GPCR	 agonists	 induces	
phosphorylation	of	PKD1	at	Ser-203	in	the	N-terminal	end.	The	study	identified	group	I	
p21-activated	 kinase	 (PAK)	 as	 novel	 upstream	 kinase	 to	 phosphorylate	 Ser-203	 and	
activate	PKD1	in	an	PKC-independent	manner.	They	showed	that	this	mechanism	leads	
to	 translocation	of	 PKD1	 into	 the	nucleus	where	 it	 regulates	HDAC5	 localization	and	
phosphorylation	[41].	
Thus,	 not	 all	 possibilities	 of	 PKD1	 regulation	 and	 activation	 can	 be	 explained	 by	 the	
PKC-pathway	and	are	yet	to	be	found.	






and	 intracellular	 localization	 (plasma	 membrane,	 trans-Golgi	 Network,	 nucleus,	
mitochondria).	Many	different	processes	on	cellular	 level	were	shown	to	 incorporate	
PKD	 in	 regulation	 of	 proliferation,	 differentiation,	 cell	 motility,	 apoptosis,	 gene	






level,	 meaning	 cancer	 progression.	 For	 example,	 fibroblasts	 stimulated	 with	 Gq-
receptor	 agonist	 induce	 mitogenesis	 of	 fibroblasts	 via	 PKD1	 activation	 [38].	 More	
detailed,	 Gq-receptor-mediated	 activation	 of	 PKD	 enhances	 ERK	 signaling	 in	
MEK/ERK/RSK	 (MEK,	 ERK	 kinase;	 ERK,	 extracellular-regulated	 protein	 kinase;	 RSK,	
ribosomal	s6	kinase)	pathway	and	therefore	potentiates	DNA	synthesis	 in	 these	cells	
[43].	 In	 epidermal	 keratinocytes,	 PKD1	 is	 more	 expressed	 during	 proliferation	 but	
lower	during	differentiation	of	keratinocytes	[44].	In	these	cells,	the	proliferative	effect	
of	 PKD	 is	 also	 attributed	 to	 activation	 of	 ERK-pathway	 and	 enhanced	DNA	 synthesis	
[45].	Regulation	 in	differentiation	processes	by	PKD1	were	 shown	 in	osteoblasts	and	
formation	 of	 bone	 [38].	Moreover,	 PKD1	 plays	 an	 important	 role	 in	 angiogenesis,	 a	





Furthermore,	 PKD1	 is	 involved	 in	 motion	 and	migration	 of	 cells	 by	 interacting	 with	
actin	 cytoskeleton	 in	 various	 aspects.	 Active	 slingshot	 phosphatase	 (SSH)	 family	
member	 SSH1L	 binds	 to	 filamentous	 actin	 (F-actin),	 dephosphorylates	 and	 therefore	
activates	cofilin	 (F-actin	depoymerization	and	severing	 factor	ADF/cofilin)	 inducing	F-
actin	polymerization	and	cell	migration.	Active	PKD1	co-localizes	with	SSH1L	to	F-actin,	
phosphorylates	and	 inactives	SSH1L	and	therefore	 inhibits	F-actin	 reorganization	and	
cell	motility	[47].	Furthermore,	PKD1	interrupts	F-actin	remodelling	by	phosphorylating	
RIN1	(Rab	interactor-1)	and	cortactin	[48,	49].	








activation	 loop	 through	PKC.	 Fully	 activated	PKD1	 in	 turn	activates	nuclear	 factor	 κB	
(NF-κB),	a	transcriptional	factor	that	protects	from	oxidative-stress-induced	cell	death,	
through	 the	 action	 of	 IκB-kinase	 β	 (IKKβ)	 of	 the	 IKK-complex	 [37,	 51].	 In	
neurodegenerative	 diseases,	 PKD1	 was	 identified	 as	 a	 key	 kinase	 to	 support	 cell	
survival	and	protect	neurons	from	oxidative	stress,	which	was	also	attributed	to	PKC-
dependent	 phosphorylation	 in	 PKD1s	 activation	 loop	 [52].	 Moreover,	 in	
cardiomyocytes	activation	of	PKD1	was	shown	to	be	mediated	by	RhoA,	a	guanosine	
triphosphatase	activated	by	GPCR	 leading	 to	PLCe	 activation	and	generation	of	DAG.	
Active	 PKD1	 phosphorylates	 and	 therefore	 inhibits	 SSH1L	 in	 cardiomyocytes,	 which	
diminishes	 oxidative-stress	 induced	 translocation	 of	 cofilin	 2	 to	 mitochondria,	





PKD1	 was	 also	 shown	 to	 regulate	 transcription.	 Specifically,	 PKD1	 phosphorylates	
specific	 sites	 of	 class	 II	 histone	 deacetylases	 (HDAC),	 which	 suppress	 transcription.	
PKD1-dependent	phosphorylation	of	members	of	class	 II	HDACs	 (HDAC4,	HDAC5	and	
HDAC7)	 promotes	 its	 dissociation	 from	 the	 chromatin	 and	 nuclear	 export	 and	
therefore	promotes	transcription	of	the	target	genes	[37].	This	mechanism	is	especially	
important	in	regulation	of	heart	remodeling	after	hypertrophic	stimuli.	Mice	deficient	




response	 element-binding	 protein	 (CREB)	 [55].	 In	 the	 context	 of	 heart	 remodeling	






Also	 in	 B	 and	 T	 lymphocytes	 PKD	 shows	 regulatory	 involvement	 in	 immunological	









Hence,	 inhibition	 of	 PKD1	 by	 MAPK	 p38δ	 enhances	 neutrophil	 recruitment	 and	
migration	[58].	Also,	PKD	was	found	to	be	part	of	 immune	response	signaling	of	toll-




At	 the	TGN	PKD1	activity	 is	 required	 for	 fission	of	 vesicles	acting	as	 carries	between	
TGN	and	plasma	membrane	 [59].	Additionally,	 PKD1	 is	 involved	 in	 cell	 secretion,	 for	
instance	 of	 aldosterone	 and	 cortisol	 from	 adrenocortical	 cells,	 or	 of	 insulin	 from	
pancreatic	β-cells	[38].	Moreover,	in	pancreatic	β-cells	PKD1	activity	is	subjected	to	the	
control	 of	 other	 stress	 activated	 kinase,	 namely	 MAPK	 p38δ,	 which	 inhibits	 its	
activation	and	suppresses	insulin	vesicle	fission	from	TGN.	Consistently,	PKD1	is	pivotal	
in	 carbachol	 (mimicking	parasympathetic	 stimulation)	 and	 glucose	 stimulated	 insulin	
secretion	 from	pancreatic	 β-cells.	Deletion	of	 PKD1	 in	 these	 cells	 results	 in	 inhibited	
insulin	secretion	upon	glucose	stimulation.	Accordant	with	that,	PKD1	 is	activated	by	
deletion	 of	 p38δ	 which	 leads	 to	 improved	 glucose	 tolerance	 by	 enhanced	 insulin	
secretion	 [42].	 Furthermore,	PKD	 is	 involved	 in	 insulin	 granule	degradation	 in	β-cells	
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and	PKDs	activity	decreases	at	the	TGN	upon	starvation	of	these	cells	suggesting	that	
nutrients	 regulate	PKDs	activity	 [60].	 It	was	also	demonstrated	that	PKD1	 is	 required	
for	 glucose-stimulated	 insulin	 secretion	 via	 G-protein	 receptor	 (GPR)	 40	 upon	




PKD1s	 multiple	 functions	 in	 fundamental	 cellular	 processes	 are	 associated	 with	
development	of	cancer.	However,	classification	in	positive	or	negative	effects	of	PKD1	
expression	on	cancer	disease	depends	on	tissue	and	cancer	cell	type	[38,	62].		
In	breast	as	well	 as	gastric	 cancer,	PKD1	expression	was	 found	 to	be	downregulated	
due	to	epigenetic	hypermethylation	of	PKD1s	promoter	region	[63,	64].	Furthermore,	
upregulation	 of	 PKD1	 inhibits	 invasiveness	 and	metastasis	 of	 breast	 cancer	 through	
decrease	 of	 cell	 migration	 via	 phosphorylation	 and	 inactivation	 of	 slingshot	
phosphatase	1L	(SSH1L),	phosphorylation	of	cortactin,	and	phosphorylation	of	Ras	and	
RIN1	 [62].	 Also,	 PKD1	 activity	 inhibits	 expression	 of	 pro-invasive	 matrix	
metalloproteinases	 (MMP)	 in	 breast	 as	 well	 as	 prostate	 cancer	 cells	 [62,	 64].	
Additionally,	 PKD1	 activity	 in	 breast	 and	 prostate	 cancer	 regulates	 epithelial-
mesenchymal-transition	 (EMT)	 through	 phosphorylation	 of	 transcription	 factor	 Snail	
(SNAI1)	 at	 Ser-11,	 which	 leads	 to	 E-cadherine	 expression,	 and	 therefore	 preventing	
EMT	process	[64,	65].	However,	other	studies	indicate	that	upregulation	of	PKD1	has	a	
pro-oncogenic	effect	on	prostate	cancer	development	[62].	 In	pancreatic	cancer	cells	
overexpression	 of	 PKD1	 was	 observed	 to	 promote	 cancer	 progress	 through	
neurotensin-induced	 synthesis	 of	 DNA	 via	 MAPK/ERK	 kinase	 1	 and	 ERK2	 [66].	
Importantly,	 inhibition	 of	 PKD1	 and	 PKD2	 was	 shown	 to	 reduce	 pancreatic	 tumor	
growth	and	to	be	a	potential	target	for	pancreatic	tumor	therapy	[67].		
1.2.2 Role	of	PKD1	in	mouse	adipose	tissue		
As	 mentioned	 above,	 adipocytes	 play	 a	 pivotal	 role	 in	 development	 of	 metabolic	
diseases	(1.1.3).	To	investigate	factors	influencing	development	of	obesity	other	than	
disadvantageous	 life-style,	multiple	approaches	were	used	 to	understand	 the	 impact	
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of	 heritability,	 specifically	 genetic	 and	 epigenetic	 influence	 on	 obesity	 and	 T2DM.	 A	
genome-wide	 association	 study	 implicated	 that	 common	genetic	 variation	 can	 cause	
approximately	 21	 percent	 of	 BMI	 variation	 in	 humans	 [68].	 Using	 genome-wide	
significance	 single	 nucleotide	 polymorphisms	 (SNP),	 this	 study	 investigated	 the	 link	





that	PKD1	plays	a	pivotal	 role	 in	 regulation	of	adipocyte	 function.	 It	 is	of	notice	 that	
PKD1	 is	 predominately	 expressed	 in	 subcutaneous	 (subWAT),	 epigonadal	 (epiWAT),	















Figure	3:	Mona	 Löffler	 et	 al.,	 unpublished.	PKD1	deficiency	 in	 adipose	 tissue	protects	 from	high	 fat	
diet-induced	 obesity.	 Body	 weight	 gain	 (A)	 over	 24	 weeks	 of	 HFD	 or	 ND	 in	 mice	 expressing	
(PKD1flox/flox,	wt)	or	deficient	 (PKD1adipo.	Δ/Δ,	ko)	 for	PKD1	 in	adipose	 tissue.	Food	 intake	 (B),	mouse	














weight	 loss	 [9].	 Hence,	 in	 living	 organism,	 energy	 intake	 can	 be	measured	with	 the	




body.	 Energy	 can	 also	 be	 utilized	 by	 the	 organism	 for	 physical	 activity	 as	 well	 as	
sustaining	 optimal	 core	 body	 temperature	 in	 the	process	 of	 adaptive	 thermogenesis	
[22].	To	test	all	of	these	possibilities,	G.	Sumara	research	group	placed	PKD1adipo.	Δ/Δ	
mice	 in	 the	 Phenomaster	metabolic	 cages	which	 allows	 simultaneous	 assessment	 of	
the	food	intake,	voluntary	movements	(activity),	O2	consumption	and	CO2	dissipation	
in	 living	 mice.	 PKD1adipo.	 Δ/Δ	 mice	 presented	 normal	 food	 intake	 (Figure	 3,	 B)	 and	
voluntary	movements	 (Figure	 3,	 C)	 compared	 to	wild-type	 littermates	when	 fed	with	
HFD.	However,	 deficiency	of	 PKD1	 specifically	 in	 adipocytes	 resulted	 in	 increased	O2	
consumption	and	higher	CO2	dissipation	(Figure	3,	D	and	E)	 indicating	elevated	energy	
expenditure	in	these	animals.		
Adipocytes	 are	 the	 main	 regulators	 of	 lipid	 levels	 in	 the	 circulation	 (1.1.2).	 As	
mentioned	 above,	 adipocytes	 secrete	 FFA	 in	 the	 process	 of	 lipolysis	 [14].	 Of	 note,	
PKD1adipo.	Δ/Δ	mice	 present	 reduced	 FFA	 levels	 compared	 to	 the	 control	mice	when	




mice	 is	 not	 altered	 by	 deletion	 of	 PKD1,	 we	 postulate	 that	mice	 deficient	 for	 PKD1	
specifically	 in	adipocytes	present	 increased	energy	expenditure	due	 to	 the	enhanced	
metabolic	activity	of	adipocytes.			
However,	the	precise	mechanism	of	PKD1-dependent	regulation	of	energy	expenditure	






In	 adipose	 tissue,	 imbalance	 of	 energy	 homeostasis	 by	 excessive	 energy	 intake	 over	
energy	dissipation	and	excessive	TG	accumulation	in	these	cells	results	in	obesity,	and	
eventually	 in	 development	 of	 metabolic	 diseases	 [1,	 14,	 22].	 PKD1	 is	 involved	 in	
regulation	 of	 many	 diverse	 physiological	 and	 pathophysiological	 processes	 in	
vertebrates	[30,	36-38,	62],	(1.2.1).	However,	the	role	of	PKD1	in	adipocytes	physiology	
and	 pathophysiology	 has	 not	 been	 fully	 understood.	 Also,	 physiological	mechanisms	
regulating	PKD1	in	adipocytes	are	still	not	known.		
Therefore,	 this	 study	 focused	 on	 three	 specific	 goals:	 The	 first	 one	 was	 the	
identification	 of	 physiological	 conditions	 that	 regulate	 PKD1	 protein	 levels,	 PKD1	







PKD1	 with	 altered	 activity,	 distribution	 of	 PKD1	 within	 the	 cell	 was	 analyzed	 using	
immunofluorescent	staining.	













All	 experiments	 on	 cells	 from	 the	 cell	 culture	 were	 performed	 with	 3T3-L1	 mouse	
embryonic	 fibroblasts	 (ATCC®	 CL-173™)	 obtained	 from	 the	 American	 Type	 Culture	
Collection.	Cells	were	grown	and	differentiated	into	adipocytes	as	described	in	3.1.		
2.2 Mouse	models	








Animal	 experiments	were	 approved	by	 the	 local	 institutional	 animal	 care	 (Regierung	
von	 Unterfranken,	 Germany)	 and	 conform	 to	 regulations	 of	 state.	 Animal	 protocol	
number	AK	55.2-2531.01-124/13,	approved	on	28.01.2014.			
2.3 siRNA	and	accessories	
To	knock	down	PKD1	and	ATGL	 in	adipocytes	 from	cell	 culture	small	 interfering	RNA	
(siRNA)	 was	 used.	 With	 the	 method	 called	 RNA	 interference	 (RNAi)	 siRNA	 has	 the	
ability	to	cleave	complementary	mRNA	targets	and	therefore	silence	its	protein	[70].		
All	 products	 were	 purchased	 from	 Dharmacon™	 GE	 Healthcare	 and	 prepared	 as	
recommended	 in	protocols	provided	by	 the	company.	One	volume	of	Dharmacon	5x	
siRNA	Buffer	 (Cat.-No.:	B-002000-UB-100)	was	diluted	 in	 four	volumes	of	RNAse-free	
water	 (Cat.-No.:	 B-002000-WB-100)	 to	 generate	 a	 1x	 solution	 in	 which	 siRNA	 was	
resuspended	 to	 a	20	μM	stock.	 To	ensure	quality	 for	 every	use,	 the	 suspension	was	




































Electroporation	 technique	 with	 4D-NucleofectorTM	 X	 Unit	 was	 used	 to	 introduce	
plasmids	 to	cells.	 For	both,	3T3-L1	pre-adipocytes	and	 fully	differentiated	adipocytes	
SE	Cell	Line	4D-Nucleofector®	X	Kit	L	(24	RCT)	was	purchased	from	Lonza.		
All	 Flag-tagged	 PKD1	 plasmids	 including	 wild	 type	 (wt),	 kinase	 dead	 (kd),	 and	
constitutive	active	(ca)	forms	as	well	as	the	non-expressing	empty	vector	were	kindly	
provided	by	Romeo	Ricci	(Institute	of	Cell	Biology,	ETH	Zurich,	Switzerland)	and	stored	
at	 our	 laboratory	 of	 G.	 Sumara	 research	 group.	 Constitutively	 active	 kinase	 is	
generated	by	mutation	of	murine	PKD1	at	ser-744	and	ser-748	sites	 to	glutamic	acid	




































































































































































































































































































































3T3-L1	 cells	 were	 cultured	 using	 protocol	 provided	 by	 ATCC	 briefly	 summarized	 as	
follows.	Standard	incubation	procedures	were	performed	at	37	°C,	95%	humidity	and	a	
5%	CO2	concentration	maintained	by	a	suitable	incubator.	Medium	was	always	heated	
to	37	 °C	before	use	except	when	stated	differently.	 FCS	and	FBS	were	 inactivated	 in	
water	bath	at	56	°C	for	30	minutes	and	aliquoted	in	50	ml	tubes	to	be	stored	at	-20	°C.	









3T3-L1	 cells	were	 grown	 in	 growth	medium	composed	of	DMEM	high	 glucose,	 10	%	
FCS,	 and	 0.4	 %	 gentamicine	 in	 100	 mm	 tissue	 culture	 dishes	 with	 a	 total	 of	 10	 ml	
growth	 medium	 per	 dish	 in	 an	 incubator	 for	 proliferation.	 Growth	 medium	 was	
exchanged	every	2	–	3	days	to	obtain	appropriate	concentrations	as	recommended	by	
ATCC.	If	sub-culturing	of	cells	was	intended,	cells	were	not	allowed	to	reach	more	than	
approximately	70	%	confluence	 [73].	 In	 this	 case,	 growth	medium	was	 removed	and	
cells	on	 the	dish	were	gently	washed	with	PBS.	2.0	ml	Trypsin	was	added	onto	each	
dish	 and	 kept	 in	 the	 incubator	 for	 approximately	 2	minutes	 until	 cells	 could	 detach.	
The	new	passage	of	cells	was	collected,	spun	down,	and	resuspended	in	growth	media	
to	 be	 split	 onto	 tissue	 culture	 dishes	 again.	 For	 experiments,	 passage	 numbers	 no	
higher	than	11	were	used.	
3.1.1 3T3-L1	adipocyte	differentiation	
In	 order	 to	 induce	 differentiation	 of	 3T3-L1	 pre-adipocytes	 into	 adipocytes	 as	
recommended	 by	 ATCC,	 cells	 were	 grown	 to	 confluence	 and	 maintained	 post-
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confluent	 for	48	hours	 [73].	Then,	growth	medium	was	 replaced	with	differentiation	
medium	 composed	 of	 DMEM	 high	 glucose,	 10	 %	 FBS,	 0.4	 %	 gentamicine,	 1.0	 μM	
dexamethasone,	0.5	mM	IBMX,	and	1.0	μg/ml	Insulin.	After	48	hours	of	incubation	the	
medium	 again	 was	 replaced	 by	 maintenance	 medium	 containing	 only	 DMEM	 high	







and	washed	 off	 with	 ice-cold	 PBS	 again.	 This	 preparation	 supports	 reattachment	 of	
adipocytes	 and	 prevents	 detachment	 concurrently,	 since	 mature	 adipocytes	 rather	
float	on	the	surface	of	liquids.	Meanwhile,	media	was	removed	from	the	adipocytes	in	
the	 100	mm	 dish	 and	 4	ml	 of	 accutase	 solution	 was	 spread	 on	 each	 dish.	 After	 10	
minutes	of	incubation	adipocytes	started	to	detach,	were	washed	off	the	dish	with	the	
maintenance	media,	and	pipetted	in	a	50	ml	tube.	The	tube	containing	the	adipocytes	
was	 then	 centrifuged	 at	 125	 x	 g	 for	 5	 minutes.	 The	 supernatant	 was	 removed	 and	
remaining	 cell	 pellet	 was	 dissolved	 in	 regular	 maintenance	 media	 for	 counting	 and	
proper	 distribution	 into	 the	 prepared	 6-	 or	 12-well	 dish	 at	 a	 certain	 cell	 density	 as	
described	in	the	experiments.		
3.1.3 Transfection	of	cells	using	siRNA	
Transfection	 was	 performed	 when	 3T3-L1	 adipocytes	 reached	 state	 of	 full	











dilution	 factor	 with	 tryptan	 blue	 (2)	 and	 the	 factor	 of	 Neubauer	 counting	 chamber	
(10,000)	which	gives	the	total	amount	of	cells	per	milliliter	[74].		
	
For	 efficient	 siRNA	 transfection	of	 3T3-L1	 adipocytes	1.16	 x	 105	 cells/cm2	were	used	












plasmids	 via	 electroporation	 using	 Lonza’s	 4D-NucleofectorTM	 technology.	 The	 cell-
specific	protocol	and	program	were	provided	by	Lonza.	According	to	the	manufacturer,	
the	 program	 CM-137	 was	 used	 to	 transfect	 3T3-L1	 pre-adipocytes	 and	 CM-133	 for	
adipocytes	 [76].	Minor	 changes	 were	 undertaken	 when	 plating	 transfected	 cells	 for	
immunofluorescent	 staining:	One	100	μl	 cuvette	was	 spread	on	4	wells	 of	 a	 12-well	
plate	 containing	 cover	 slips	 prepared	 with	 0.5	 %	 matrigel	 coating	 as	 stated	 before	
(3.1).	 This	 approach	 guaranteed	 well-distributed	 and	 less	 overlaying	 cells	 on	 slides	
allowing	 better	 examination	 under	 the	 microscope.	 Transfected	 cells	 were	 kept	 in	
culture	for	24	hours	until	further	analyzed.	




For	 immunofluorescent	 staining,	 cells	 were	 plated	 on	 cover	 slips	 in	 12-well	 plates	
(3.1.4).	 The	 cells	 were	 washed	 with	 PBS	 3	 times	 before	 fixation	 with	 4	 %	
paraformaldehyde	 in	PBS	at	 room	 temperature	 for	10	minutes	 [77].	After	washing	3	
times	 with	 PBS	 the	 cells	 were	 permeabilized	 with	 0.1	 %	 triton	 X-100	 in	 PBS	 for	 15	
minutes	at	room	temperature.	Cells	were	blocked	with	2	%	BSA	in	PBS	for	1	hour	until	
repeatedly	washed	 and	 ready	 for	 antibody	 incubation.	 To	 save	 supplies	 of	 antibody	
incubation	 process,	 cover	 slips	 were	 transferred	 on	 parafilm	 placed	 inside	 a	 wet	
chamber.	





containing	 primary	 antibody	 only.	 Again,	 cover	 slips	were	washed	 3	 times	with	 PBS.	
Then,	 they	 were	 covered	 with	 phalloidin-iFluor	 555	 reagent	 according	 to	 the	
manufacturers	 (abcam)	 instructions	 in	PBS	1	%	BSA	 for	90	minutes.	 Thereafter,	 they	
were	 washed	 3	 times	 with	 PBS	 again.	 Approximately	 50	 μl	 mounting	 medium	
containing	 DAPI	 was	 used	 to	 fixate	 cover	 slips	 on	 the	 glass-slides	 and	 co-stain	 the	
nucleus.	 Finished	 slides	 were	 then	 kept	 in	 the	 dark	 at	 4	 °C.	 Analysis	 under	 the	
microscope	was	possible	one	day	after	mounting.	The	primary	and	secondary	negative	







each	were	withdrawn	 from	 food	 for	 either	 12	 hours	 over	 night	 or	 for	 24	 hours.	 Of	
these,	three	mice	were	refed	in	each	experimental	group	after	12	or	24	hours	again.		
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For	 experimental	 comparison	 of	 PKD1	 response	 to	 normal	 and	 high	 fat	 diet	 (4.2),	 8	
mice	were	fed	with	ND	supplied	by	the	institutes	animal	house	and	7	mice	with	high	





After	 mice	 were	 sacrificed	 via	 cervical	 dislocation,	 epigonadal	 white	 adipose	 tissue	
(epiWAT)	 was	 quickly	 taken	 from	 the	 abdomen,	 subcutaneous	 white	 adipose	 tissue	
(subWAT)	 from	 abdominal	 skin,	 and	 brown	 adipose	 tissue	 (BAT)	 from	 interscapular	
depot	 [1].	 The	 tissue	 samples	was	 then	 portioned	 in	 2	ml	 tubes	 and	 flash	 frozen	 in	
liquid	nitrogen	for	long	time	storage.		
3.2.2 Mouse	adipose	tissue	explants	
For	 direct	 experiments	 on	 explants	 as	 in	 the	 isoproterenol	 stimulation	 experiments	







After	 the	medium	 had	 been	 removed,	 cells	 were	 collected	 by	 pipetting	 150	 μl	 lysis	
















Generally,	 quantities	 between	 15	 to	 50	 ug	 of	 protein	were	 used	 depending	 on	 how	
well	proteins	of	interest	were	detectable.	The	desired	quantity	of	protein	solution	was	
pipetted	 into	 tubes.	 To	 balance	 the	 difference	 of	 volume	 to	 the	most	 concentrated	
sample	of	one	experiment,	 lysis	buffer	was	added,	 so	 that	all	 samples	had	 the	same	






The	 separated	 proteins	 were	 transferred	 onto	 a	 polyvinylidene	 difluoride	 (PVDF)	





TBST	 3	 times	 for	 15	 minutes	 at	 room	 temperature,	 and	 incubated	 with	 primary	
antibodies	diluted	in	TBST	5	%	BSA	at	90	rpm	as	follows:	
	
	 Dilution	 Incubation	 kDa	
PKD1	 1:2000	 4°C	over	night	 115	
	 37	
PKD1	(Ser916)	 1:1000	 4°C	over	night	 115	
PKD1	(Ser744/748)	 1:1000	 4°C	over	night	 115	
ATGL	 1:5000	 4°C	over	night	 54	
PKD2	 1:1000	 4°C	over	night	 105	
PKD3	 1:1000	 4°C	over	night	 110	







The	 membrane	 was	 washed	 3	 times	 with	 TBST	 again	 before	 it	 was	 incubated	 with	








1	ml	QIAzol	per	well,	 thoroughly	scratched	off	 the	plate,	collected	 in	2	ml	 tubes	and	
rapidly	 frozen	 on	 dry	 ice.	When	 analyzing	 RNA	 of	 epiWAT,	 subWAT,	 and	 BAT	 taken	
from	mice	(3.2.1),	samples	were	homogenized	with	bench-top	homogenizer	at	15	Hz	
for	2	minutes	in	2	ml	tubes	containing	1	ml	QIAzol	and	flash	frozen	in	liquid	nitrogen.	
Samples	 could	 either	 be	 stored	 at	 -80	 °C	 or	 processed	 directly.	 Before	 processing,	
frozen	 samples	 needed	 to	 defreeze	 on	 ice.	 In	 order	 to	 extract	 RNA,	 samples	 were	
processed	 acting	 on	 the	 suggestion	 of	 quick-start	 protocol	 provided	 by	 QIAGEN	
starting	from	step	3	[78].		
	
RNA	 was	 quantified	 with	 NanoDrop	 2000	 c	 spectrophotometer.	 2.0	 μl	 RNAse	 free	
water	was	used	as	blank	and	concentration	(in	μg/ml)	of	nucleic	acid	was	measured	in	
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2.0	 μl	 of	 each	 RNA	 solution	 with	 absorbance	 at	 230nm,	 260nm,	 and	 280nm.	 To	




whereas	 lower	 260nm/280nm	 ratios	 indicate	 contamination	with	 protein	 or	 reagent	
[79].	
	
Reverse	 transcription	 of	 RNA	 into	 complementary	 DNA	 (cDNA)	 was	 conducted	 with	
First	 Strand	 cDNA	 Synthesis	 Kit.	 Random	 hexamer	 primer	 provided	 by	 the	 kit	 were	
used	 to	 ensure	 that	 all	 RNA	 was	 transcribed.	 An	 oligo(dT)18	 primer	 binds	 only	
messenger	RNA	(mRNA)	with	poly(A)	tail	and	was	not	used	in	this	study.	Following	the	

































consisting	 one	 step	 denaturation	 of	 the	 double	 strand	 DNA	 (95°C	 for	 15	 seconds),	
annealing	 of	 the	 primers	 to	 the	 single	 stranded	 DNA,	 and	 elongation	where	 DNA	 is	
synthesized	 using	 DNA	 polymerase	 (primer	 dependent	 temperature	 (2.6)	 for	 60	







sample	 were	 transferred	 to	 fresh	 starvation	 medium.	 For	 stimulation	 of	 lipolysis,	
samples	were	incubated	in	medium	containing	10	μM	isoproterenol	for	2	hours.		
FFAs	 in	 medium	 of	 the	 samples	 were	 quantified	 using	 NEFA-HR(2)	 reagent	 (Wako)	
according	 to	 manufacturers’	 instructions.	 Glycerol	 was	 measured	 with	 free	 glycerol	
reagent	(Sigma-Aldrich)	also	as	described	by	the	manufacturer.	
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When	 samples	 of	 lipolysis	 experiments	 were	 tested	 for	 RNA	 levels	 with	 qRT-PCR,	












4.1 Regulation	 of	 PKD1	 expression	 in	 adipocytes	 in	 response	 to	 different	
physiological	conditions		
Activity	of	adipocytes	depends	on	the	amount	of	nutrients	available	for	the	organism.	
Generally,	 upon	 excessive	 food	 ingestion	 adipocytes	 absorb	 the	 nutrients	 from	
circulation	and	convert	 them	into	TG	[1].	 In	contrast,	during	 food	deprivation	TG	are	
degraded	 in	 the	 process	 of	 lipolysis	 to	 produce	 FFA	 and	 glycerol	 [14].	 G.	 Sumaras	
research	 group	 showed	 that	 inactivation	of	 PKD1	 specifically	 in	 adipocytes	 results	 in	
pronounced	effect	on	function	of	these	cells	(1.2.2).	
4.1.1 Adipose	tissue	specific	expression	of	PKD1	in	response	to	fasting	and	feeding	
To	 investigate	 regulation	of	PKD1	activity	 and	PKD1	expression	or	 abundance	during	
feeding-fasting-cycles,	Western	Blot	and	RT-qPCR	were	used	in	the	first	experiment.		
In	a	preliminary	experiment	conducted	by	M.	Löffler,	epigonadal	white	adipose	tissue	
(epiWAT)	 was	 isolated	 from	 mice	 fed	 ad	 libidum,	 prolonged	 (24	 hours,	 h)	 fasted	
animals,	and	mice,	which	were	fasted	for	24	h	and	re-fed	for	the	same	period	of	time.	





activity	 in	 epiWAT	 as	 assessed	 by	 Western	 Blot	 using	 antibody	 against	 PKD1	
phosphorylated	 on	 serine	 916	 (Figure	 4,	 A	 and	 B).	 Interestingly,	 re-feeding	 of	 mice	
brought	 phosphorylation	 of	 PKD1	 on	 serine	 916	 to	 the	 levels	 observed	 in	 adipose	
tissue	 of	 unfastened	 animals	 (Figure	 4,	 A	 and	 B,	 PKD1ser916).	 Reduced	 levels	 of	
phosphorylated	 PKD1	 might	 be	 caused	 by	 diminished	 upstream	 mechanism	
phosphorylating	 this	 kinase	 or	 by	 lower	 total	 levels	 of	 PKD1	 protein.	 To	 understand	




























fasting,	 TGs	 stored	 in	 adipocytes	 are	 hydrolyzed	 in	 the	 process	 of	 lipolysis	 [14].	





Figure	 5:	 Increased	 lipolysis	 and	 decreased	 PKD1	 expression	 in	mouse	 epiWAT	 upon	 isoproterenol	
stimulation.	EpiWAT	was	taken	from	one	mouse	and	dissected.	After	1	hour	of	starvation	in	a	medium	
containing	high	glucose	DMEM	and	0.5	%	FFA-free	BSA	explants	were	either	 transferred	 to	starvation	






murine	 adipose	 tissue	 was	 confirmed:	 Glycerol	 levels	 were	 significantly	 elevated	
compared	to	no	stimulation	(Figure	5,	A).	It	is	of	notice	that	isoproterenol	is	an	agonist	
of	 β-adrenergic	 receptor,	 a	 GPCR,	 and	 induces	 cardiomyocyte	 hypertrophy	 in	 mice	
through	 the	 actions	 of	 PKD1	 [54].	 Therefore,	 the	 effect	 of	 isoproterenol-inducted	




PKD1	expression.	This	 statistically	 significant	 reduction	corresponds	with	 the	 findings	
in	adipose	tissue	of	fasted	mice	(Figure	4,	C	and	D).		
However,	 adipose	 tissue	 is	 heterogeneous	 and	 also	 contains	 blood	 vessels,	 nerves,	





Figure	 6:	 3T3-L1	 adipocytes	 show	 decreased	 PKD1	 expression	 upon	 isoproterenol	 stimulation.	 Cells	
were	 incubated	 in	 starvation	 medium	 for	 1	 hour.	 Then	medium	 was	 exchanged	 either	 to	 starvation	
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Next,	 it	 was	 analyzed	 whether	 enhanced	 lipolysis	 and	 its	 products	 can	 directly	 be	
associated	 with	 the	 decrease	 of	 PKD1	 expression	 in	 adipocytes	 (4.1.2)	 or	 whether	
isoproterenol	 is	 responsible	 for	 this	 effect	 independently	 from	 lipolysis.	 Therefore,	




















(cont.)	 to	 adipocytes	 transfected	 with	 non-targeting	 siRNA	 (siCtrl)	 one	 can	 see	 that	
transfection	only	minimally	affects	physiological	ATGL	expression	after	24	hours	(Figure	
7,	 B,	 24	 hours).	 However,	 when	 treated	 with	 siCtrl	 for	 48	 hours,	 little	 reduction	 of	
physiological	ATGL	protein	 levels	were	observed	 (Figure	7,	 B,	 48	hours).	 Thus,	 further	
experiments	with	transfection	were	conducted	after	24	hours	and	results	were	always	
compared	to	siCtrl-transfected	cells.		
Next,	 lipolysis	 essay	 was	 performed	 with	 transfected	 adipocytes	 at	 basal	 as	 well	 as	
isoproterenol-stimulated	 status.	 The	 basal	 TG	 lipolysis	 in	 3T3-L1	 adipocytes	 is	 not	
altered	 between	 siATGL-	 and	 siCtrl-transfected	 cells	 (Figure	 8,	 A	 and	 B,	 control).	 But	
when	 stimulated	 with	 isoproterenol	 to	 enhance	 lipolysis,	 glycerol	 and	 FFA	 levels	 of	
siATGL-adipocytes	 remain	 low	 while	 values	 of	 siCrtl-treated	 adipocytes	 significantly	
increase.	 It	 is	 striking	 that	cells	 transfected	with	siATGL	have	significantly	diminished	
glycerol	and	FFA	levels	upon	isoproterenol	stimulation	compared	to	siCtrl-cells	(Figure	8,	
A	 and	 B).	 This	 is	 in	 line	 with	 findings	 of	 Scheiger	 et	 al.	 [16]	 suggesting	 that	 ATGL	
silencing	 effectively	 inhibits	 production	 of	 lipolytic	 products	 when	 stimulated	 with	
isoproterenol.		
Analysis	 of	 transcriptional	 levels	 showed	 that	 ATGL	 silencing	 does	 not	 significantly	
affect	PKD1	expression	 in	3T3-L1	adipocytes	 (Figure	8,	C,	 control).	Upon	 isoproterenol	
stimulation,	 PKD1	 expression	 is	 down	 regulated	 in	 both	 control	 and	 ATGL-silenced	
adipocytes.	Altogether,	these	results	might	 indicate	that	 isoproterenol	 independently	
















exposed	 to	 starvation	 medium	 for	 2	 hours	 and	 either	 starvation	 medium	 was	 changed	 (Control,	
n=4/siRNA	type)	or	medium	with	10	μM	isoproterenol	was	added	(n=4/siRNA	type).	After	2	hours	FFA-	










and	 sucrose)	 for	 24	 weeks	 until	 obesity	 was	 induced	 in	 these	 mice	 (Figure	 3,	 A,	
PKD1flox/flox	HFD).		
Here,	adipose	tissue	of	mice	at	the	condition	of	over-nutrition	described	above	were	



















Western	 blot,	 level	 of	 the	 phosphorylated	 form	PKD1	 ser-916,	which	 represents	 the	
activated	form	of	PKD1,	appears	to	be	higher	in	mice	fed	with	ND	than	mice	on	HFD,	
too.	These	results	stand	in	contrast	to	the	findings	in	RT-qPCR.	Interestingly,	a	second	
lower	 band	 appears	 at	 approximately	 90	 kDa	 after	 incubation	 of	 Western	 blot	
membrane	with	 total	PKD1-Antibody.	 It	has	a	pattern	opposed	to	 the	upper	band	of	




Function	and	activity	 status	of	PKD1	 is	associated	with	 its	 localization	within	 the	cell	
[31,	 36].	 Distribution	 of	 PKD1	 within	 the	 cell	 in	 context	 of	 function	 has	 been	
investigated	 in	human	epithelial	 cells	derived	 from	cervix	 carcinoma	 (HeLa	 cells),	 rat	
mammary	adenocarcinoma	cells	(MTLn3	cells,	[47]),	pancreatic	ductal	adenocarcinoma	
cells	 (Panc89	 cells,	 [49]),	 colorectal	 cancer	 cells	 (HCT116	 and	 SW480,	 [81]),	
dopaminergic	neuronal	cells	(N27,	[52]),	mouse	B-cell	and	T-cell	 lymphoma	cells	(A20	
and	 EL4)[57],	 amongst	 others.	 Overexpressed	 GFP-tagged	 PKD1	 was	 found	 to	 be	
localized	at	TGN	and	perinuclear	in	3T3-L1	adipocytes	before	[82].		
Here,	 an	 approach	 was	 used	 to	 analyze	 distribution	 of	 PKD1	 within	 adipocytes	 in	
different	 activation	 modes	 of	 the	 kinase.	 Therefore,	 3T3-L1	 adipocytes	 were	
transfected	with	plasmids	overexpressing	PKD1	as	wild	type,	constitutively	active,	and	
as	 kinase	 that	 cannot	 be	 phosphorylated	 and	 therefore	 not	 activated	 (kinase	 dead)	





Figure	10:	PKD1	 localization	changes	 in	3T3-L1	adipocytes	depending	on	PKD1	activity	status.	 In	this	
immunofluorescence	 analysis,	 cells	 were	 transfected	 with	 plasmids	 containing	 flag-tagged	 control	
(empty),	wildtype	PKD1	(PKD1-WT),	constitutively	active	PKD1	(PKD1-CA),	or	kinase-dead	PKD1	(PKD1-
KD).	 After	 24	 hours,	 proteins	 were	 detected	 with	 anti-flag	 primary	 antibody	 and	 alexa	 fluor®	 568	




Control	 adipocytes	with	 plasmids	 expressing	 nonfunctional	 protein	 depicted	 no	 flag-
tagged	 protein	 (Figure	 10,	 empty).	 Expression	 of	 wild	 type	 PKD1	 led	 to	 perinuclear	




involved	 in	 vesicle	 fission	 at	 trans-golgi-network	 (TGN),	 an	organelle	 associated	with	
perinuclear	position,	too	[42].	Furthermore,	this	experiment	showed	that	kinase	dead	
PKD1	was	 scattered	mostly	 in	 cytoplasm	with	 irregular	 pattern	 (Figure	 10,	 PKD1-KD).	
This	 is	accordant	with	findings	in	resting	cells,	where	PKD1	is	predominantly	found	in	
the	cytosol	and	translocates	to	organelles	when	stimulated	[30,	31].	Collectively,	these	
results	display	 that	association	of	PKD1	activity	with	 translocation	of	PKD1	 in	3T3-L1	
adipocytes	can	be	found.		
Interestingly,	 different	 patterns	 of	 fat	 vacuole	 formation	 within	 the	 cell	 can	 be	
observed.	Adipocytes	transfected	with	plasmids	expressing	constitutively	active	PKD1	




activity	 status	 on	 fat	 content	 in	 adipocytes	 could	 be	 observed.	 This	 indicates	 that	
either	 active	 PKD1	 supports	 lipogenesis	 and	 fat	 accumulation	 in	 adipocytes	 or	 that	

















mice	 expressing	 adiponectin	 promotor-driven	Cre	 recombinase	 to	 generate	mice	deficient	 of	 PKD1	 in	









Figure	 12:	 PKD1	 deficiency	 did	 not	 affect	 induced	 lipolysis	 in	 epiWAT	 from	mice.	 PKD1flox/flox	 and	
PKD1adipo.Δ/Δ	 epiWAT	 explants	 were	 starved	 in	 medium	 for	 2	 hours.	 Explants	 were	 either	 further	
incubated	 in	 starvation	medium	 (control)	or	 stimulated	with	medium	containing	10	μM	 isoproterenol	
for	2	hours.	Lipolysis	rate	was	estimated	by	measuring	FFA	(A)	and	glycerol	(B)	levels	in	the	medium.	For	
FFA	measurements,	PKD1	flox/flox	control	n=10	and	stimulated	n=11.	For	glycerol	measurements,	PKD1	




Basal	 FFA	 and	 glycerol	 levels	 did	 not	 reveal	 differences	 between	 PKD1flox/flox	 and	
PKD1adipo.Δ/Δ	 (Figure	 12,	 control).	 Upon	 isoproterenol	 stimulation	 lipolytic	 products	
increased	in	medium	of	both,	PKD1	expressing	and	PKD1	deficient	epiWAT	(Figure	12,	10	
μM	Isoproterenol).	Hence,	lipolysis	in	PKD1adipo.Δ/Δ	epiWAT	was	not	enhanced	at	basal	
rate	 nor	 when	 stimulated	 with	 isoproterenol	 compared	 to	 wild	 type	 epiWAT.	










low	 calorie	 intake	 [14].	 It	 is	 arguable	whether	 these	 findings	 result	 from	higher	 FFA	
consumption	 in	cells	of	mice	 lacking	PKD1	in	white	adipocytes	or	from	increased	FFA	
consumption	 in	 other	 organs.	 It	 was	 shown	 before	 that	 increase	 of	 oxygen	
consumption	 and	 loss	 of	 bodyweight	 due	 to	 stimulation	 of	 A2A	 receptors	 in	murine	
white	adipose	tissue	can	be	attributed	to	elevation	of	browning	markers	in	these	cells	
[83].	 Therefore,	 another	 possible	 explanation	 for	 low	 peripheral	 FFA	 levels	 in	
association	with	diminished	PKD1	expression	was	addressed.	 In	the	next	experiment,	
thermogenic	 markers	 that	 can	 be	 found	 in	 brown	 adipose	 tissue	 were	 determined.	
















tissue.	 Results	were	 statistically	 significant	 for	 epiWAT,	 subWAT	 and	 BAT.	 Strikingly,	









function	 is	 to	 isolate	 body	 from	 loss	 of	 temperature	 to	 environment	 and	 beige	
adipocytes	 are	 found	mainly	 in	 subcutaneous	WAT	 [2,	 5].	 In	 comparison,	 UCP1	 and	
other	 BAT-specific	 genes	 remain	 almost	 unchanged	 in	 of	 PKD1flox/flox	 and	








The	 key	 functions	 of	 PKD1	 in	 many	 diverse	 physiological	 and	 pathophysiological	
processes	 in	 vertebrates	 have	 been	 described	 and	 discussed	 before	 [30,	 36-38,	 62],	
(1.2.1).	 Studies	 focusing	 on	 metabolism	 discovered	 the	 importance	 of	 PKD1	 in	
metabolic	 processes:	 Sumara	 et	 al.	 revealed	 that	 active	 PKD1	 enhances	 insulin	
secretion	 from	pancreatic	b-cells	 and	 thus	 protects	 from	glucose	 intolerance	 [42].	 A	
genome-wide	 association	 study	 using	 significance	 SNPs,	 found	 association	 of	 PKD1	
gene-locus	with	BMI	[68].	Results	of	M.	Löffler	in	G.	Sumara	research	group	indicated	
that	 PKD1-deficiency	 specifically	 in	 adipose	 tissue	 protects	 against	 HFD-induced	
obesity	(Figure	3,	A)	and	leads	to	elevated	energy	expenditure	in	mice	(Figure	3,	D	and	E).	
However,	 the	 specific	 metabolic	 function	 of	 PKD1	 in	 adipocytes	 has	 not	 been	 fully	
understood.	Also,	physiological	mechanisms	regulating	PKD1	activity	in	adipocytes	are	
still	not	known.	Elucidating	these	was	the	aim	of	this	study.	
This	 study	 showed	 that	 PKD1	 activity	 and	 expression	 in	 white	 adipose	 tissue	 is	
dependent	 on	 the	 nutritional	 status	 of	 mice.	 Specifically,	 expression,	 protein	
abundance	 and	 activity	 of	 PKD1	 is	 down	 regulated	 during	 fasting	 (4.1.1).	 Of	 note,	
results	of	this	study	indicate	that	expression	of	PKD1	is	not	depending	on	the	induction	
of	lipolysis	and	its	products	but	only	on	b-adrenergic	stimulation	of	adipocytes	(4.1.2),	
which	 is	 a	 primary	 signal	 inducing	 fasting	 program	 in	 adipocytes	 [15,	 20].	 However,	
reduction	 of	 β-adrenergic	 stimulated	 lipolysis	 did	 not	 affect	 the	 expression	 of	 PKD1	
(4.1.3).	 Subsequently,	 this	 study	 showed	 that	 consumption	 of	 high	 caloric	 nutrients	
induced	expression	of	PKD1	RNA	but	paradoxically	did	not	induce	higher	levels	of	PKD1	
protein	in	epiWAT	of	mice	(4.2).	Furthermore,	the	results	presented	here	indicate	that	
action	of	PKD1	 in	 adipocytes	 is	 regulated	not	only	on	 the	 transcriptional	 level	but	 is	
also	 affected	 by	 its	 intracellular	 distribution.	 This	 study	 showed	 that	 activated	 PKD1	
was	 distributed	 primarily	 around	 the	 nucleus,	 while	 inactive	 PKD1	 presented	
perinuclear	 and	 nuclear	 localization	 in	 murine	 adipocytes	 (4.3).	 In	 addition	 to	
unraveling	 how	 activity	 of	 PKD1	 is	 regulated,	 the	 study	 investigated	 its	 impact	 on	
aspects	of	 adipocyte	physiology.	 Specifically,	 the	obtained	 results	 indicate	 that	PKD1	
did	 not	 regulate	b-adrenergic	 stimulated	 lipolysis	 (4.4).	 However,	 this	 study	 showed	
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One	goal	of	 this	 study	was	 to	 identify	 the	physiological	mechanisms	 regulating	PKD1	
expression	 and	 activity	 in	white	 adipocytes.	 This	 study	 demonstrated	 that	 fasting	 of	
mice	 significantly	 reduced	 expression	 of	 PKD1	 as	 well	 as	 phosphorylation	 and	
therefore	activation	of	PKD1	in	white	adipocytes	(Figure	4).		
Fasting	 is	 a	 physiological	 condition	 under	 which	 stimulation	 of	 the	 sympathetic	
nervous	 system	 is	 necessary	 for	 survival	 of	 living	 organisms	 to	 increase	 lipolysis.	
Catecholamines	trigger	signaling	cascades	at	β-adrenergic	receptors	 in	adipose	tissue	
in	response	to	food	deprivation	or	fasting	finally	leading	to	lipolysis	in	these	cells	[20,	
89].	 This	process	 can	be	 imitated	by	 isoproterenol	 [90].	 The	present	 study	displayed	
that	 12	 h	 of	 fasting	 of	 mice,	 as	 shown	 in	 24	 h,	 led	 to	 reduction	 of	 PKD1	 RNA	 and	
protein	 levels	 in	white	 adipose	 tissue	 (Figure	4).	Moreover,	 the	 results	 demonstrated	
that	isoproterenol	stimulation	induced	generation	of	lipolytic	products	in	murine	white	
adipose	 tissue	 as	 well	 as	 in	 3T3-L1	 adipocytes	 and	 the	 same	 stimulation	 lowered	
expression	of	PKD1	in	these	cells	(Figure	5,	Figure	6).	This	indicates	involvement	of	PKD1	
in	the	process	of	lipolysis.		
Wang	 et	 al.	 showed	 that	 the	 transcription	 factor	 peroxisome	 proliferator-acitvated	
receptor	 δ	 (PPARδ)	 plays	 a	 pivotal	 role	 in	 release	 of	 TGs	 and	β-oxidation	 in	 adipose	
tissue	 [91].	 Furthermore,	 Iglesias	 et	 al.	 identified	 that	 deletion	 of	 PPARβ/δ	 in	
pancreatic	 β-cells	 leads	 to	 an	 enhanced	 PKD1	 expression	 and	 protein	 activation,	
indicating	 regulatory	 effect	 of	 PPAR	 on	 PKD1	 [92].	 Several	 FFA	 derivatives	 act	 as	
endogenous	 agonists	 for	 PPARδ	 transcription	 and	 activity	 [93].	 Takahashi	 et	 al.	
suggested	that	fasting	could	generate	FFA	acting	as	 ligands	for	PPARδ	in	muscle	cells	
and	inducing	expression	of	genes	implicated	in	β-oxidation	[94].	Therefore,	assumably	
PKD1	 RNA	 levels	 could	 be	 decreased	 in	 fasted	 adipocytes	 because	 of	 increased	








also	 be	 activated	 by	 β-adrenergic	 stimulation	 [20,	 95].	 In	 this	 mechanism,	
catecholamines	 bind	 β-adrenergic	 receptors	 enhancing	 cAMP	 levels	 and	 activity	 of	
protein	kinase	A	(PKA).	On	one	the	hand,	PKA	phosphorylates	cAMP	element	binding	
protein	 (CREB)	 transcription	 factor	 to	 induce	 PGC-1	 gene	 expression.	 On	 the	 other	
hand,	 cAMP	activates	MAP	kinase	p38α	 to	phosphorylate	and	excite	PGC-1α	activity	
which	finally	coactivates	PPARγ	in	metabolic	gene	expression	[20].	Transcription	factor	
PPARγ	 plays	 a	 pivotal	 role	 in	 lipid	 and	 glucose	 metabolism	 and	 adipocyte	
differentiation	and	is	found	especially	in	adipocytes	[96].	Thus,	β-adrenergic	activation	
of	 PGC-1α	 and	 PPARγ	 could	 be	 possible	 mechanisms	 explaining	 reduced	 PKD1	
expression	 under	 isoproterenol	 stimulation	 of	 white	 adipocytes	 in	 the	 experiments	
conducted	in	this	study.	However,	Motillio	et	al.	showed	that	accumulation	of	lipolytic	
products	 in	 white	 adipocytes	 upon	 β-adrenergic	 stimulation	 lead	 to	 lower	 PKA-
mediated	expression	of	PGC-1α	and	UCP-1	mRNA	level	[97].	This	stands	in	contrast	to	
findings	presented	in	this	study,	that	ATGL	silencing	and	suppression	of	lipolysis	had	no	
impact	 on	 PKD1	 expression.	 Therefore,	 further	 analysis	 on	 FFA-dependent	 and	 –
independent	 regulation	 of	 PKD1	 expression	 is	 necessary	 to	 understand	 upstream	
mechanisms	in	this	process.	Also,	dependency	of	PKD1	gene	expression	on	PGC-1α	and	
PPARγ	in	adipocytes	needs	to	be	further	investigated.	
In	 the	 expression	 of	 PKD1,	 PKD1	 promoter	 is	 crucial	 and	 can	 be	 epigenetically	
regulated	 [98,	 99].	 Ay	 et	 al.	 revealed	 that	 inhibition	 of	 histone	 deacetylase	 (HDAC)	
increases	 PKD1	 promoter	 activity	 and	 PKD1	 expression	 [98].	 Also,	 inhibition	 of	
methylation	 of	 PKD1	 promoter	 at	 CpG-islands	 increased	 PKD1	 expression.	
Furthermore,	they	identified	PKD1	promoter	in	MN9D	dopaminergic	neuronal	cells	as	





activity	 in	 rat	 kindeys	 [101].	 Thus,	 fasting	of	mice	 in	 the	 experiment	presented	here	
could	 hypothetically	 lower	 NF-κB	 levels	 and	 therefore	 attenuate	 PKD1	 promoter	




RNA	 levels,	 this	study	showed	that	phosphorylation	and	therefore	activity	of	PKD1	 is	
reduced	 in	WAT	upon	fasting	of	mice	(Figure	4,	A	and	B,	PKD1-Ser916),	a	process	that	
induces	lipolysis	and	generation	of	 lipolytic	products	[14].	Furthermore,	Western	blot	
showed	 that	 not	 only	 PKD1-Ser916	 but	 also	 total	 PKD1	 was	 downregulated	 upon	
fasting.	Therefore,	 it	 is	unclear	whether	PKD1	was	downregulated	only	as	a	 result	of	
attenuated	transcription	or	if	other	mechanisms	reduced	PKD1	activity	as	well.	
DAG	acts	as	 secondary	messenger	of	 cell	 surface	 receptors	 to	bind	and	activate	PKD	
[30].	 Thus,	 the	 question	 arises	 if	 DAGs	 derived	 from	 TG	 lipolysis	 have	 potential	 to	
activate	 PKD1,	 too.	However,	 this	 study	 showed	 that	 fasting	 did	 not	 stimulate	 PKD1	
activity	but	induce	the	opposite	(Figure	4,	A	and	B,	PKD1-Ser916).	It	has	been	discussed	
before	 that	 lipolysis	 of	 TGs	 by	ATGL	display	DAGs	with	 stereoisomeric	 (1,3-DAG	and	
2,3-DAG)	and	locational	differences	to	1,2-DAG	which	serves	as	signaling	mediator	and	
activator	of	PKC	[15].		














is	 possibly	 regulated	 by	 transcriptional	 mechanisms	 in	 which	 transcription	 factor	
PPARγ	 and	 coactivator	 PGC-1α	 in	 context	 of	b-adrenergic	 stimulation,	 or	 epigenetic	






and	 activation	 in	 white	 adipocytes	 was	 put	 on	 the	 state	 of	 food	 abundance	 under	




Results	of	M.	 Löffler	 from	G.	 Sumara	 research	group	 showed	 that	mice	deficient	 for	





with	plasmids	 led	 to	overexpression	of	 constitutively	 active	PKD1,	3T3-L1	adipocytes	
displayed	 a	 phenotype	with	many	 filled	 fat	 vacuoles	whereas	 adipocytes	 expressing	
non-functional	PKD1	(PKD1-KD)	showed	poorer	fat	accumulation,	indicating	that	PKD1	
supports	 fat	 accumulation	 in	 3T3-L1	 adipocytes,	 too	 (Figure	 10).	 Therefore,	 it	 seems	
likely	 that	 PKD1	 plays	 an	 important	 role	 in	 the	 process	 of	 adaptation	 to	 food	
abundance	in	adipocytes.		
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In	 the	 process	 of	 adipogenesis	 as	 well	 as	 lipogenesis	 and	 TG	 storage,	 PPARγ	 is	 the	
pivotal	transcription	factor	that	activates	gene	expression	of	proteins	involved	in	these	












regulated	 by	 KRas,	 binds	 to	 PKD1	 promoter	 and	 enhances	 PKD1	 expression	 in	
pancreatic	cancer	cells	[104].	NF-κB	is	a	transcriptional	factor	involved	in	the	processes	
of	inflammation	and	development	of	metabolic	diseases	[100].	It	was	shown	that	HFD	




Therefore,	PKD1	and	NF-κB	might	 function	 in	an	amplification	 signaling	 loop	 in	HFD-
induced	WAT	expansion,	as	described	before	 in	pancreatic	cancer	 [104].	Hence,	high	
PKD1	 RNA	 levels	 in	 HFD-induced	 obese	 mice	 of	 this	 study	 might	 also	 underlie	
regulation	of	PKD1	promoter	through	NF-κB	activity.	Thus,	regulatory	role	of	NF-κB	on	
PKD1	 and	wise	 versa	 in	 obesity	 display	 an	 interesting	 target	 for	 further	 research	 in	
development	and	treatment	of	obesity	and	metabolic	diseases.	
	
Taken	 together,	 results	 of	 this	 study	 strongly	 suggest	 involvement	 of	 PKD1	 in	
regulatory	mechanisms	directing	fat	accumulation	in	WAT,	making	PKD1	an	interesting	
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target	 for	 metabolic	 disease	 therapy.	 Expression	 of	 PKD1	 in	 response	 to	 food	
abundance	possibly	 include	the	transcription	 factor	PPARγ	or	HFD-induced	activation	
of	 NF-κB.	 Their	 interaction	 in	 adipocytes	 upon	 HFD	 could	 be	 focus	 of	 future	
experiments.	 Elucidating	 mechanisms	 inhibiting	 growth	 and	 expansion	 of	 white	




Next	 to	PKD1	RNA	 levels,	 this	 study	examined	PKD1	protein	 activity	 in	HFD-exposed	
mice	 using	 Western	 blot	 (Figure	 9,	 B).	 Surprisingly,	 PKD1	 protein	 levels	 were	
upregulated	 in	 epiWAT	 of	mice	 fed	ND	 and	 downregulated	when	 fed	HFD,	which	 is	
contrary	 to	 RT-qPCR	 results	 of	 PKD1	 RNA	 levels	 (Figure	 9,	 A).	 However,	 total	 PKD1	
protein	detection	also	exhibited	a	band	at	approximately	90	kDa,	which	has	a	pattern	
opposed	to	the	upper	band	of	115	kDa.	The	90	kDa	band	is	stronger	in	epiWAT	of	mice	
fed	 HFD	 and	 lowers	 upon	 ND.	 This	 might	 indicate	 that	 in	 response	 to	 HFD	 PKD1	
undergoes	posttranslational	modification	or	 is	 alternatively	 transcribed	 to	produce	a	
lower	molecular	weight	form	in	WAT.	
Increased	food	intake	and	obesity	are	known	to	induce	hypertrophy	and	hyperplasia	of	
adipocytes,	 that	 can	 cause	 hypoxia	 and	 macrophage	 invasion	 [1,	 9,	 28,	 106].	
Furthermore,	 adipocyte	 hypertrophy	 due	 to	 obesity	 in	 mice	 leads	 to	 pro-apoptotic	
gene	expression	and	eventually	 to	cell	apoptosis	 in	white	adipose	tissue	through	the	
actions	of	caspase	3	amongst	others	[107,	108].	During	induction	of	apoptosis	caspase	
3	 was	 found	 to	 cleave	 PKD1	 in	 the	 C1-PH	 interdomain	 generating	 active	 PKD1	
fragments	[109,	110].	This	led	to	consideration	whether	low	molecular	weight	of	PKD1	
in	hypertrophic	adipose	tissue	of	HFD	fed	mice	could	be	due	to	cleavage	and	activation	
of	PKD1	 in	 these	 cells.	 In	neurons,	oxidative	 stress	was	 shown	 to	activate	PKD1	 in	 a	
PKC-dependent	 manner	 and	 protect	 neuronal	 cells	 from	 apoptosis	 [52].	 Hence,	 in	
neurons	 PKD1	 showed	 anti-apoptotic	 function	 [52],	 whereas	 caspase	 3,	 besides	
activating	PKD1	[110],	mediates	apoptosis	 in	hypertrophic	adipocytes	of	diet-induced	




by	 anti-apoptotic	 function	 of	 PKD1	 in	 hypertrophic	 white	 adipose	 tissue.	 However,	
there	are	certain	disagreements	to	consider.	First,	Asaithambi	et	al.	detected	cleaved	
product	 of	 PKD1	 at	 a	 size	 of	 approximately	 60	 kDa	 [52],	 a	 smaller	 protein	 than	 the	
protein	detect	 in	 this	study.	Vantus	et	al.	additionally	 found	a	PKD1	fragment	at	100	
kDA	after	 incubation	with	caspase-3,	 -6,	 -8	or	-11	showing	that	other	caspases	might	
also	 process	 PKD1	 [39].	 Second,	 in	 this	 study,	 PKD1-Ser916	 presenting	 the	 activated	
form	of	 PKD1,	 is	 stronger	 detected	 in	Western	 blot	 of	 adipose	 tissue	 from	mice	 fed	
with	 ND	 and	 not	 HFD	 (Figure	 9,	 B).	 And	 third,	 besides	 posttranslational	 protein	









In	 the	 experimental	 approach	 of	 adipocyte	 transfection	 and	 staining,	 correlation	
between	 activity	 status	 of	 PKD1,	 its	 localization	 within	 3T3-L1	 adipocytes	 and	 the	
phenotype	these	cells	exhibit	was	analyzed	(Figure	10).	It	is	known	that	biological	effect	
of	 PKD1	 is	 linked	 to	 its	 intracellular	 localization	 [36-38].	 Here,	 we	 show	 that	 non-
functional	 PKD1	 (PKD1-KD)	 is	 predominantly	 found	 in	 the	 cytoplasm	 of	 3T3-L1	
adipocytes	 (Figure	 10),	 as	 it	 is	 known	 of	 inactive	 PKD1	 in	 resting	 cells	 [30,	 31].	
Interestingly,	PKD-KD	transfected	cells	contain	only	few	fat	vacuoles	compared	to	the	
control	adipocytes	 indicating	 that	an	enhanced	TG	 lipolysis	 took	place	or	 lipogenesis	
was	 suppressed.	 Moreover,	 PKD1-WT	 and	 PKD1-CA	 accumulate	 perinuclear	 and	
intranuclear	 in	 adipocytes	 where	 the	 latter	 display	 many	 round	 fat	 vacuoles,	
suggesting	that	enhanced	fat	accumulation	occurred	(Figure	10,	PKD1-WT	and	-CA).	This	
	 64	
is	 concordant	 with	 RT-qPCR	 results	 of	 HDF-induced	 obese	 mice,	 where	 PKD1	 was	
highly	 expressed	 (Figure	 9).	 Recent	 study	 in	muscle	 cells	 identified	 a	 novel	 upstream	
target	 of	 PKD1:	 It	 phosphorylates	 and	 therefore	 inactivates	 AMP-activated	 protein	








Furthermore,	 activated	 PKD1	 is	 known	 to	 translocate	 to	 nucleus	 and	 also	 presents	
perinuclear	localization	[30].	PKD1	regulates	vesicle	fission	from	TGN,	which	is	located	
perinuclear	 [59].	Study	 in	pancreatic	β-cells	 showed	that	PKD1	activity	at	TGN	 led	 to	
insulin	 vesicle	 fission	 and	 insulin	 secretion	 [42].	 Other	 study	 in	 3T3-L1	 adipocytes	
suggested	that	PKD1	activity	could	partially	regulate	leptin	vesicle	trafficking	at	TGN,	as	
a	 kinase	 dead	 mutant	 resulted	 in	 significant	 decrease	 of	 leptin	 secretion	 [82].	
Therefore,	 PKD1	 assumably	 supports	 TGN	 trafficking	 to	 plasma	 membrane	 in	
adipocytes	and	possibly	contributes	to	adipocyte	endocrine	function,	too.		
In	 nucleus,	 PKD1	 is	 known	 to	 regulate	 transcription	 through	 the	 actions	 of	 class-IIa	
HDAC	[37].	 In	epithelial	cells,	active	PKD1	was	shown	to	translocate	of	PKD1	into	the	
nucleus	where	it	regulates	HDAC5	localization	and	phosphorylation	[41].	Thus,	nuclear	
accumulation	 of	 PKD-WT	 and	 PKD-CA	 indicate	 that	 activated	 PKD1	 enhances	 gene	
transcription	in	adipocytes.	
However,	besides	nucleus	no	other	cellular	organelle	was	stained	 in	this	experiment,	
so	 that	 position	 of	 PKD1	 in	 adipocytes	 cannot	 directly	 be	 related	 to	 specific	
localization.	 Also,	 in	 this	 experimental	 approach	 quantitative	 measurement	 of	 fat	
content	 in	 adipocytes	 was	 not	 performed.	 Therefore,	 a	 precise	 conclusion	 about	
phenotype	 and	 fat	 content	 in	 adipocytes	 is	 not	 possible	 but	 a	 tendency	 can	 be	
observed.	Hence,	 this	 experimental	 approach	 supports	 the	 assumptions	 drawn	 from	
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PKD1	 ablation	 in	white	 adipose	 tissue	 does	 not	 have	 an	 impact	 on	 isoproterenol-
induced	lipolysis	but	induces	browning	of	these	cells		
Focus	 of	 this	 study	 was	 not	 only	 the	 identification	 of	 physiological	 conditions	
regulating	PKD1	but	also	testing	PKD1-dependency	on	mechanisms	regulating	energy	
expenditure	in	murine	adipocytes.	In	G.	Sumara	research	group,	M.	Löffler	was	able	to	
show	 that	 PKD1adipo.Δ/Δ	 mice	 fed	 with	 HFD	 gained	 less	 weight	 than	 wild	 type	
littermates	(Figure	3,	A,	PKD1adipo.Δ/Δ	and	PKDf/f	HFD).	In	this	study,	3T3-L1	adipocytes	






of	 lipolytic	 products	 at	 basal	 status	 nor	was	 the	 lipolysis	 rate	 different	 to	wild	 type	






Furthermore,	 in	 the	 study	of	M.	Löffler	mice	 fed	with	ND	did	not	develop	obesity	 in	
comparison	 to	mice	 fed	with	HFD	 (Figure	3,	 A).	 In	 fact,	 consumption	of	 energy-dense	
food	 high	 in	 fat	 is	 the	 main	 reason	 for	 obesity	 and	 metabolic	 disease	 in	 high-	 and	
middle-income	countries,	next	to	physical	inactivity	[23].	To	balance	energy	equation,	
excessive	 calorie-intake	 needs	 to	 be	 compensated	 through	 a	 higher	 energy	
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expenditure.	Otherwise	 the	energetic	 imbalance	 leads	 to	 increased	 fat	 accumulation	
and	 adipocyte	 growth	 [1,	 23].	 In	 PKD1adipo.Δ/Δ	mice	 fed	 HFD,	 M.	 Löffler	 measured	
significantly	 lower	 FFA-blood	 levels	 as	well	 as	 increased	O2	 consumption	 and	 higher	






[1,	 5].	 In	 the	 presented	 study,	 deletion	 of	 PKD1	 specifically	 in	 adipocytes	 led	 to	
browning	of	WAT	in	mice	fed	with	HFD	(4.5).	UCP-1,	most	important	marker	for	brown	
and	 beige	 adipocytes	 [5],	 was	 increased	 in	 epiWAT	 PKD1adipo.Δ/Δ	 over	 110-fold	
compared	 to	 PKD1flox/flox	 epiWAT,	 and	 in	 subWAT	 UCP-1	 expression	 was	 8.9-fold	
higher	 in	PKD1adipo.Δ/Δ	 than	 in	PKD1flox/flox	subWAT	 (Figure	13,	A	and	B).	Both	 results	
were	 statistically	 significant.	 Additionally,	 other	 browning	 markers	 such	 as	 Slc27a,	
Cidea,	 and	 Cox8b	 [84-87]	 were	 significantly	 elevated	 in	 PKD1adipo.Δ/Δ-epiWAT	 and	
Cox8b	in	PKD1adipo.Δ/Δ-subWAT	(Figure	13,	A	and	B).	Expression	of	those	genes	was	not	
affected	 in	 PKD1flox/flox	 and	 PKD1adipo.Δ/Δ	 BAT	 of	 mice	 fed	 with	 HFD	 (Figure	 13,	 C).	
Together,	 these	 findings	 demonstrate	 that	 deletion	 of	 PKD1	 in	 adipocytes	 led	 to	
browning	 in	 epigonadal	 and	 subcutaneous	WAT	without	 affecting	 BAT.	 Browning	 or	





fed	 HFD	 [116].	 Furthermore,	 Gnad	 et	 al.	 discussed	 that	 increase	 of	 oxygen	










of	 future	 experiments.	 Also,	 browning-marker	 and	 energy	 expenditure	 could	 be	
analyzed	 in	PKD1-deficient	adipocytes	 in	an	 in	vitro	experiment,	 for	example	as	used	
before	 in	 the	 case	 of	 Prdm16	 using	 stroma	 vascular	 cells	 from	 subWAT	 of	 mice	
transduced	with	adenovirus	expressing	shRNA	targeted	to	PKD1	[116].	Not	to	 forget,	
increased	 oxygen	 consumption	 can	 be	 attributed	 to	 increased	mitochondrial	 activity	
and	to	higher	amount	of	mitochondrial	content	in	adipose	tissue	of	mice,	as	has	been	
shown	by	Wilson-Fritch	et	al.	[117].	It	would	be	interesting	to	investigate	differences	in	
respiration	 rate	 and	mitochondrial	 content	 in	 adipose	 tissue	 of	 PKD1-deficient	mice	
and	their	wildtype	littermates	in	future	experiments.	
	
Another	 consideration	 is	 possible	 in	 the	 context	 that	 ablation	 of	 PKD1	 induced	
browning	 in	 white	 adipose	 tissue	 (4.5)	 and	 findings	 of	 PKD1	 protein	 detection	 in	
epiWAT	 of	 mice	 on	 HFD	 (4.2).	 Possibly,	 PKD1	 is	 cleaved	 not	 with	 gaining	 an	 active	
status	but	with	 loss-of-function	 in	adipose	 tissue	of	mice	on	HDF	 (Figure	9,	B)	 so	 that	
excessive	calories	can	be	dissipated	through	induction	of	browning	at	a	certain	point	in	
time	rather	than	stored.	Western	blot	revealed	loss	in	activity	of	PKD1	upon	HFD,	too	









used	 as	 pharmaceutical	 in	 treatment	 of	 T2DM	 but	 are	 associated	with	 body	weight	
gain	 rather	 than	 loss,	 cardiovascular	 dysfunction,	 and	 others,	 so	 that	 application	 in	
humans	was	strictly	limited	[118,	119].	Thus,	targeting	PKD1	function	in	white	adipose	
tissue	in	obese	could	offer	a	new	therapeutic	approach	to	prevent	obesity,	metabolic	












a	physiological	 condition	which	 induces	 lipolysis.	 Isoproterenol-stimulated	 lipolysis	 in	
adipose	tissue	and	3T3-L1	adipocytes	reduced	PKD1	gene	expression.	Silencing	ATGL	in	
adipocytes	 inhibited	 isoproterenol-stimulated	 lipolysis,	 however,	 the	 b-adrenergic	
stimulation	of	ATGL-silenced	adipocytes	lowered	PKD1	expression	levels	as	well.		
Adipose	tissue	of	obese	mice	exhibited	high	PKD1	RNA	levels	but	paradoxically	 lower	
protein	 levels	 of	 phosphorylated	 PKD1-Ser916.	 However,	 HFD	 generated	 a	 second	
PKD1	protein	product	of	low	molecular	weight	in	mouse	adipose	tissue.		
Furthermore,	 constitutively	active	PKD1	predominantly	displayed	nuclear	 localization	
in	 3T3-L1	 adipocytes	 containing	 many	 fat	 vacuoles.	 However,	 adipocytes	
overexpressing	non-functional	PKD1	contained	fewer	 lipid	droplets	and	PKD1-KD	was	
distributed	in	cytoplasm.	
Most	 importantly,	 deficiency	 of	 PKD1	 in	mouse	 adipose	 tissue	 caused	 expression	 of	







Adipozyten	 sind	 spezialisierte	 Zellen	 der	 Wirbeltiere,	 die	 das	 Überleben	 durch	
Anpassung	 an	 Nahrungsmangel	 und	 Nahrungsüberfluss	 gewährleisten.	 Eine	
Dysfunktion	 von	 Adipozyten	 bedingt	 jedoch	 die	 Pathophysiologie	 von	
Stoffwechselerkrankungen	wie	 dem	 T2DM.	 Vorläufige	 Ergebnisse	 von	Mona	 Löfflers	
Versuchen	zeigten,	dass	PKD1	in	der	Funktion	von	Adipozyten	involviert	ist.		
Innerhalb	dieser	Arbeit	 konnte	dargestellt	werden,	 dass	 die	 Expression	und	Aktivität	
von	 PKD1	 in	 murinen	 Adipozyten	 an	 den	 Lipidmetabolismus	 gekoppelt	 ist.	 Beim	
Hungern	 von	 murinem	 weißen	 Fettgewebe,	 einem	 physiologischen	 Zustand,	 der	
Lipolyse	 induziert,	 war	 die	 Genexpression	 von	 PKD1	 reduziert.	 Isoproterenol-
stimulierte	Lipolyse	führte	ebenfalls	zu	verminderter	Expression	von	PKD1	in	murinen	
weißen	 Fettgewebe	 und	 3T3-L1	 Adipozyten.	 In	 ATGL-silenced	 Adipozyten	 war	 die	
Isoproterenol-stimulierte	 Lipolyse	 zwar	 inhibiert,	 allerdings	wurde	die	Genexpression	
von	PKD1	durch	die	b-adrenerge	Stimulation	ebenfalls	vermindert.		
Fettgewebe	von	adipösen	Mäusen	hingegen	wiesen	hohe	PKD1	RNA	Level	sowie	einen	
niedrigen	 Proteingehalt	 der	 phosphorylierten	 Form	 PKD1-Ser916	 auf.	 Fettreiche	
Ernährung	 von	 Mäusen	 generierte	 in	 Fettgewebe	 jedoch	 ein	 weiteres	 Produkt	 von	
PKD1	mit	niedrigem	Molekulargewicht	im	Western	Blot.		
Des	Weiteren	wurde	 dargestellt,	 dass	 konstitutiv	 aktives	 PKD1	 in	 3T3-L1	 Adipozyten	
vorwiegend	 nuklear	 lokalisiert	 war	 und	 diese	 Adipozyten	 einen	 hohen	 Gehalt	 von	
Fettvakuolen	aufwiesen.	Adipozyten,	die	funktionsloses	PKD1	exprimierten,	enthielten	
wenige	Lipidtropfen	und	PKD1-KD	war	im	Cytoplasma	verteilt		
Vor	 allem	 zeigte	 diese	 Arbeit,	 dass	 die	 Deletion	 von	 PKD1	 spezifisch	 in	 murinem	
Fettgewebe	 die	 Expression	 von	 Genen	 wie	 UCP-1	 verursachte,	 die	 eine	 Rolle	 in	
adaptiver	 Thermogenese	 spielen,	 und	 dadurch	 einen	 brown-like	 Phänotypen	
generierte.	
Zusammenfassend	ist	PKD1	in	die	Funktionen	von	Adipozyten	verwickelt	und	stellt	ein	
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